Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Clinical trials have shown that glycopyrrolate/formoterol fumarate improves lung function in patients with chronic obstructive pulmonary disease (COPD) caused by tobacco exposure. Although tuberculosis-associated COPD has worse respiratory health outcomes than smoking-associated COPD, no clinical trials have determined whether pharmacological intervention is effective. We designed a clinical trial to evaluate the safety and efficacy of glycopyrrolate/formoterol fumarate for the treatment of tuberculosis-associated COPD. Methods: , FVC, and percentage predicted FVC; and COPD Assessment Test scores. Discussion: The results of the PTB-COPD trial will provide the first insights into the pharmacological treatment of tuberculosis-associated COPD. We anticipate the results of this trial to be available in the first half of 2027. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2500103088. Registered on May 23, 2025.
Fields of Study & Subjects
Chronic Obstructive Pulmonary Disease (COPD) Research
Inhalation and Respiratory Drug Delivery
Asthma and respiratory diseases
Publication details
- Journal / source
- Journal of Thoracic Disease
- Volume
- 18
- Issue
- 3
- Pages
- 256–256
- Publication date
- 1 March 2026
- Language
- EN